The US Supreme Court has declined to review the PCMA v. Mulready case, marking a significant setback for efforts to protect patients and pharmacies from harmful practices by PBMs. This decision upholds the 10th Circuit’s ruling, which struck down key provisions of the state’s Patient’s Right to Pharmacy Choice Act on the grounds that they are preempted by ERISA and Medicare Part D. As a result, the state now faces limited options for safeguarding pharmacies and ensuring patient access to the medications they need.
For more information, contact NACDS’ Mary Staples at 817-442-1155.